50 Key Biopharmaceutical and Biotechnology Companies

  • ID: 4451241
  • Report
  • Region: Global
  • 201 Pages
  • Kalorama Information
1 of 4

FEATURED COMPANIES

  • AbbVie
  • Berry Genomics Co Ltd.
  • Enzo Biochem, Inc
  • Illumina
  • Novo Nordisk A/S
  • Roche Ltd.
  • MORE

50 Key Biopharmaceutical and Biotechnology Companies is a comprehensive look at the top 50 companies that are shaping the biotherapeutics market in 2017 and beyond. The top 50 companies in this report were chosen for a variety of reasons, including sales of marketed biopharmaceutical products, innovation in biotherapeutics, and unique additions to the market, either marketed products or products in development.

50 Key Biopharmaceutical and Biotechnology Companies
includes large traditional pharma powerhouses such as Pfizer, Novartis, Roche, Merck, GSK, Bristol-Myers Squibb, Bayer, and others; but it also includes smaller niche companies such as Genmab, Seattle Genetics, etc. In addition, it includes leading biopharmaceuticals such as Amgen and Biogen, and leading biotech companies such as Qiagen, Alexion, Agilent, Waters Co and others.

Biopharmaceuticals are therapeutic agents intended to treat symptoms and/or underlying causes of a variety of disorders and diseases. They have been a growing part of the pharmaceutical landscape since the early 1980s and is, today, one of the fastest growing areas in the pharmaceutical industry, growing at an average rate of 12%-15% over the past two years. Today, there are many biologics in the approval pipeline and it has been projected that over 65% of drugs approved for the marketplace in 2017 will be the result of biotechnology. Biopharmaceuticals hold great promise for treating some of the most intractable medical conditions such as cancer and autoimmune disease.

Biotechnology

Biotechnology is the applied knowledge of biology, it seeks to duplicate or change the function of a living cell, so it will work in a more predictable and controllable way. The biotechnology industry uses advances in genetics research to develop products for human diseases and conditions.

Biotech opportunities largely mirror those in the pharmaceutical industry. The key difference is that biotech firms are much more focused on research because they are still developing their initial products. Biotech firms tend to expand their marketing and sales forces when and if a viable product nears FDA approval.

Biopharmaceutical and Biotechnology Company Profiles

50 Key Biopharmaceutical and Biotechnology Companies profiles these market leaders in-depth, presenting detailed information about each company, including:

  • a Corporate Summary
  • Selected Biopharmaceutical Products
  • Biopharmaceuticals in Development
  • Selected Corporate Developments
  • Company Financials
  • Regional Revenue Breakdown by Percentage (%)
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Berry Genomics Co Ltd.
  • Enzo Biochem, Inc
  • Illumina
  • Novo Nordisk A/S
  • Roche Ltd.
  • MORE

1: Executive Summary
Introduction
Scope and Methodology
Market Summary

Figure 1-1: Summary: Top 10 of the Top 50 Biotechnology Companies by Biologic Revenues 2017 ($ billions)

2: Introduction
Biopharmaceuticals and Biotherapeutics
Biopharmaceuticals
Biotechnology
Areas Of Treatment For Biopharmaceuticals
Regulations For Biopharmaceuticals

3: 50 Key Biopharmaceutical and Biotechnology Companies: Profiles

ABBVIE
Table 3-1: AbbVie Corporate Summary
Company Overview
Table 3-2: Selected AbbVie Biopharmaceutical Products
Table 3-3: Selected Biopharmaceuticals in Development
Table 3-4: Selected Corporate Developments
Company Financials
Table 3-5: AbbVie (2015-2017) ($ millions)

AGILENT TECHNOLOGIES INC.
Table 3-6: Agilent Corporate Summary
Company Overview
Figure 3-1: Agilent Regional Breakdown by % (Americas, Europe, Asia Pacific, Rest of World)
Company Financials
Table 3-7: Agilent (2015-2017) ($ millions)

ALEXION PHARMACEUTICALS INC
Table 3-8: Alexion Corporate Summary
Company Overview
Figure 3-2: Alexion Regional Breakdown by % (US, Europe, Asia Pacific, Rest of World)
Table 3-9: Selected Alexion Biopharmaceutical Products
Table 3-10: Selected Alexion Biopharmaceuticals in Development
Company Financials
Table 3.11: Alexion (2015-2017) ($ millions)

ALLERGAN PLC
Table 3-12: Allergan Corporate Summary
Company Overview
Table 3-13: Selected Corporate Developments
Company Financials
Table 3-14: Allergan (2015-2017) ($ millions)

AMBRY GENETICS
Table 3-15: Ambry Genetics Corporate Summary
Company Overview

AMGEN, INC
Table 3-16: Amgen Corporate Summary
Company Overview
Figure 3-3: Amgen Regional Breakdown by % (US, Rest of World)
Table 3-17: Selected Biopharmaceutical Products
Table 3-18: Selected Amgen Biopharmaceuticals in Development
Table 3-19: Selected Corporate Developments
Company Financials
Table 3-20: Amgen (2015-2017) ($ millions)

ASTRAZENECA PLC
Table 3-21: AstraZeneca Corporate Summary
Company Overview
Figure 3-4: AstraZeneca Regional Breakdown by % (US, Europe, Japan, Rest of World)
Table 3-22: Selected Biopharmaceuticals Products
Table 3-23: Selected Biopharmaceuticals in Development
Table 3-24: Selected Corporate Developments
Company Financials
Table 3-25: AstraZeneca (2015-2017) ($ millions)

BAYER AG
Table 3-26: Bayer AG Corporate Summary
Company Overview
Figure 3-5: Bayer Regional Breakdown by % (North America, EMEA, Asia Pacific, Latin America, Rest of World)
Table 3-27: Selected Bayer AG Biopharmaceutical Products
Table 3-28: Selected Biopharmaceuticals in Development
Table 3-29: Selected Corporate Developments
Company Financials
Table 3-30: Bayer (2015-2017) ($ millions)

BERRY GENOMICS CO LTD.
Table 3-31: Berry Genomics Corporate Summary
Company Overview

BIOGEN
Table 3-32: Biogen Corporate Summary
Company Overview
Figure 3-6: Biogen Regional Breakdown by % (US, Rest of World)
Table 3-33: Selected Biopharmaceutical Products
Table 3-34: Selected Biopharmaceuticals in Development
Table 3-35: Selected Corporate Developments
Company Financials
Table 3-36: Biogen (2015-2017) ($ millions)

BIOMARIN PHARMACEUTICAL INC
Table 3-37: BioMarin Pharmaceutical Corporate Summary
Company Overview
Figure 3-7: BioMarin Regional Breakdown by % (US, Europe, Latin America, Rest of World)
Table 3-38: Selected Biopharmaceuticals Products
Table 3-39: Selected Biopharmaceuticals in Development
Company Financials
Table 3-40: BioMarin (2014-2017) ($ millions)

BRISTOL MYERS SQUIBB
Table 3-41: Bristol Myers Squibb Corporate Summary
Company Overview
Figure 3-8: BMS Regional Breakdown by % (US, Europe, Japan, Rest of World)
Table 3-42: Selected Biopharmaceutical Products
Table 3-43: Selected Biopharmaceuticals in Development
Table 3-44: Selected Corporate Developments
Company Financials
Table 3-45: BMS (2015-2017) ($ millions)

CELGENE
Table 3-46: Celgene Corporate Summary
Company Overview
Figure 3-9: Celgene Regional Breakdown by % (US, Europe, Rest of World)
Table 3-47: Selected Biopharmaceutical Products
Table 3-48: Selected Biopharmaceuticals in Development
Table 3-49: Selected Corporate Developments
Company Financials
Table 3-50: Celgene (2015-2017) ($ millions)

CRISPR THERAPEUTICS AG
Table 3-51: CRISPR Therapeutics Corporate Summary
Company Overview
Table 3-52: Selected Corporate Developments
Company Financials
Table 3-53: CRISPR (2015-2017) ($ thousand)

CSL BEHRING
Table 3-54: CSL Behring Corporate Summary
Company Overview
Table 3-55: Selected Biopharmaceutical Products
Table 3-56: Selected Biopharmaceuticals in Development
Company Financials
Table 3-57: CSL Behring (2015-2017) ($ millions)

DR. REDDY’S LABORATORIES LIMITED
Table 3-58: Dr Reddy’s Laboratories Corporate Summary
Company Overview
Company Financials
Table 3-59: Dr Reddy’s Laboratories (2015-2017) ($ millions)

ELI LILLY & CO
Table 3-60: Eli Lilly Corporate Summary
Company Overview
Figure 3-10: Eli Lilly Regional Breakdown % (US, Rest of World)
Table 3-61: Selected Biopharmaceutical Products
Table 3-62: Selected Biopharmaceuticals in Development
Table 3-63: Selected Corporate Developments
Company Financials
Table 3-64: Eli Lilly (2015-2017) ($ millions)

ENZO BIOCHEM, INC
Table 3-65: Enzo Biochem Corporate Summary
Company Overview
Company Financials
Table 3-66: Enzo Biochem (2014-2017) ($ thousands)

EVOTEC AG
Table 3-67: Evotec AG Corporate Summary
Company Overview
Figure 3-11: Evotec Regional Breakdown by % (Europe, US, Rest of World)
Table 3-68: Selected Corporate Developments
Company Financials
Table 3-69: Evotec (2015-2017) ($ Thousands)

EXELIXIS
Table 3-70: Exelixis Corporate Summary
Company Overview
Figure 3-12: Exelixis Regional Breakdown by % (US, Europe, Japan)
Table 3-71: Selected Biopharmaceutical Products
Table 3-72: Selected Biopharmaceuticals in Development
Table 3-73: Selected Corporate Developments
Company Financials
Table 3-74: Exelixis (2015-2017) ($ thousands)

GENMAB
Table 3-75: Genmab Corporate Summary
Company Overview
Table 3-76: Selected Biopharmaceutical Products
Table 3-77: Selected Biopharmaceuticals in Development
Table 3-78: Selected Corporate Developments
Company Financials
Table 3-79: Genmab (2015-2017) ($ thousands)

GILEAD SCIENCES
Table 3-80: Gilead Sciences Corporate Summary
Company Overview
Figure 3-13: Gilead Sciences Regional Breakdown by % (US, Europe, Japan, Rest of World)
Table 3-81: Selected Biopharmaceuticals in Development
Table 3-82: Selected Corporate Developments
Company Financials
Table 3-83: Gilead (2015-2017) ($ millions)

GLAXOSMITHKLINE
Table 3-84: GlaxoSmithKline Corporate Summary
Company Overview
Figure 3-14: GSK Regional Breakdown by % (US, Europe, Rest of World)
Table 3-85: Selected Biopharmaceutical Products
Table 3-86: Selected Biopharmaceuticals in Development
Table 3-87: Selected Corporate Developments
Company Financials
Table 3-88: GSK (2015-2017) ($ millions)

GRIFOLS INTERNATIONAL S.A.
Table 3-89: Grifols International S.A. Corporate Summary
Company Overview
Figure 3-15: Grifols Regional Breakdown by % (North America, Europe, Rest of World)
Table 3-90: Selected Biopharmaceutical Products
Table 3-91: Selected Corporate Development
Company Financials
Table 3-92: Grifols (2015-2017) ($ millions)

GUARDANT HEALTH
Table 3-93: Guardant Health Corporate Summary
Company Overview

ILLUMINA
Table 3-94: Illumina Corporate Summary
Company Overview
Company Financials
Table 3-95: Illumina (2015-2017) ($ millions)

INCYTE CORPORATION
Table 3-96: Incyte Corporate Summary
Company Overview
Table 3-97: Selected Biopharmaceutical Products
Table 3-98: Selected Biopharmaceuticals in Development
Table 3-99: Selected Corporate Development
Company Financials
Table 3-100: Incyte (2015-2017) ($ millions)

JOHNSON & JOHNSON
Table 3-101: Johnson & Johnson Corporate Summary
Company Overview
Figure 3-16: J&J Regional Breakdown by % (US, Europe, Asia Pacific/Africa, Rest of World)
Table 3-102: Selected Biopharmaceutical Products Table 3-103: Selected Biopharmaceuticals in Development
Table 3-104: Selected Corporate Developments
Company Financials
Table 3-105: J&J (2015-2017) ($ millions)

MERCK & CO, INC.
Table 3-106: Merck Corporate Summary
Company Overview
Figure 3-17: Merck Regional Breakdown by % (US, EMEA, Japan, Asia Pacific, Latin America, Rest of World)
Table 3-107: Selected Biopharmaceutical Products
Table 3-108: Selected Biopharmaceuticals in Development
Table 3-109: Selected Corporate Developments
Company Financials
Table 3-110: Merck (2015-2017) ($ millions)

MYLAN
Table 3-111: Mylan Corporate Summary
Company Overview
Figure 3-18: Mylan Regional Breakdown by % (North America, Europe, Rest of World)
Company Financials
Table 3-112: Mylan (2015-2017) ($ millions)

MYRIAD GENETICS
Table 3-113: Myriad Genetics Corporate Summary
Company Overview
Table 3-114: Selected Corporate Developments
Company Financials
Table 3-115: Myriad (2015-2017) ($ millions)

NOVARTIS INTERNATIONAL AG
Table 3-116: Novartis Corporate Summary
Company Overview
Figure 3-19: Novartis Regional Breakdown by % (US, Europe, Asia Pacific, Rest of World)
Table 3-117: Selected Biopharmaceutical Products
Table 3-118: Selected Biopharmaceuticals in Development
Table 3-119: Selected Corporate Developments
Company Financials
Table 3-120: Novartis (2015-2017) ($ millions)

NOVO NORDISK A/S
Table 3-121: Novo Nordisk Corporate Summary
Company Overview
Figure 3-20: Novo Nordisk Regional Breakdown by % (North America, Europe, Japan, South Korea, China, Rest of World)
Table 3-122: Selected Biopharmaceutical Products
Table 3-123: Selected Biopharmaceuticals in Development
Company Financials
Table 3-124: Novo Nordisk (2015-2017) ($ millions)

ORGANOGENESIS
Table 3-125: Organogenesis Corporate Summary
Company Overview

OXFORD NANOPORE TECHNOLOGIES
Table 3-126: Oxford Nanopore Technologies Corporate Summary
Company Overview

PERKIN ELMER, INC
Table 3-127: Perkin Elmer Corporate Summary
Company Overview
Table 3-128: Selected Corporate Developments
Company Financials
Table 3-129: PerkinElmer (2015-2017) ($ millions)

PFIZER
Table 3-130: Pfizer Corporate Summary
Company Overview
Figure 3-21: Pfizer Regional Breakdown by % (US, Japan, Rest of World)
Table 3-131: Selected Biopharmaceutical Products
Table 3-132: Selected Biopharmaceuticals in Development
Table 3-133: Selected Corporate Developments
Company Financials
Table 3-134: Pfizer (2015-2017) ($ millions)

PRECISION BIOSCIENCES INC
Table 3-135: Precision BioSciences Corporate Summary
Company Overview

QIAGEN N.V.
Table 3-136: QIAGEN Corporate Summary
Company Overview
Figure 3-22: QIAGEN Regional Breakdown by % (Americas, EMEA, Asia Pacific & Rest of World)
Table 3-137: Selected Corporate Developments
Company Financials
Table 3-138: QIAGEN (2015-2017) ($ millions)

REGENERON PHARMACEUTICALS
Table 3-139: Regeneron Corporate Summary
Company Overview
Table 3-140: Selected Biopharmaceutical Products
Table 3-141: Selected Biopharmaceuticals in Development
Table 3-142: Selected Corporate Developments
Company Financials
Table 3-143: Regeneron (2015-2017) ($ millions)

ROCHE LTD.
Table 3-144: Roche Corporate Summary
Company Overview
Figure 3-23: Roche Regional Breakdown by % (North America, Europe, Japan, Asia Pacific, Rest of World)
Table 3-145: Selected Biopharmaceutical Products
Table 3-146: Selected Biopharmaceuticals in Development
Company Financials
Table 3-147: Roche (2015-2017) ($ millions)

SANOFI
Table 3-148: Sanofi Corporate Summary
Company Overview
Figure 3-24: Sanofi Regional Breakdown by % (US, Europe, Rest of World)
Table 3-149: Selected Biopharmaceutical Products
Table 3-150: Selected Biopharmaceuticals in Development
Table 3-151: Selected Corporate Developments
Company Financials
Table 3-152: Sanofi (2015-2017) ($ millions)

SEATTLE GENETICS, INC
Table 3-153: Seattle Genetics Corporate Summary
Company Overview
Table 3-154: Selected Biopharmaceuticals in Development
Table 3-155: Selected Corporate Developments
Company Financials
Table 3-156: Seattle Genetics (2015-2017) ($ millions)

SHIRE
Table 3-157: Shire Corporate Summary
Company Overview
Table 3-158: Selected Biopharmaceutical Products
Table 3-159: Selected Biopharmaceuticals in Development
Table 3-160: Selected Corporate Development
Company Financials
Table 3-161: Shire (2015-2017) ($ millions)

TAKEDA
Table 3-162: Takeda Corporate Summary
Company Overview
Figure 3-25: Takeda Regional Breakdown by % (US, Europe, Japan, Rest of World)
Table 3-163: Selected Biopharmaceutical Products
Table 3-164: Selected Biopharmaceuticals in Development
Table 3-165: Selected Corporate Developments
Company Financials
Table 3-166: Takeda (2015-2017) ($ millions)

TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Table 3-167: Teva Corporate Summary
Company Overview
Figure 3-26: Teva Regional Breakdown by % (US, Europe, Rest of World)
Table 3-168: Selected Biopharmaceutical Products
Table 3-169: Selected Biopharmaceuticals in Development
Table 3-170: Selected Corporate Developments
Company Financials
Table 3-171: Teva (2015-2017) ($ millions)

THERMO FISHER SCIENTIFIC, INC
Table 3-172: Thermo Fisher Scientific Corporate Summary
Company Overview
Table 3-173: Selected Corporate Developments
Company Financials
Table 3-174: Thermo Fisher Scientific (2015-2017) ($ millions)

UCB S.A.
Table 3-175: UCB Corporate Summary
Company Overview
Table 3-176: Selected Biopharmaceuticals in Development
Table 3-177: Selected Corporate Developments
Company Financials
Table 3-178: UCB (2015-2017) ($ millions)

UNITED THERAPEUTICS CORPORATION
Table 3-179: United Therapeutics Corporate Summary
Company Overview
Table 3-180: Selected Biopharmaceuticals in Development
Company Financials
Table 3-181: United Therapeutics (2015-2017) ($ millions)

WATERS CORPORATION
Table 3-182: Waters Corporate Summary
Company Overview
Figure 3-27: Waters Regional Breakdown by % (US, Europe, Asia, Rest of World)
Company Financials
Table 3-183: Waters (2015-2017) ($ millions)

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie
  • Agilent Technologies Inc.
  • Alexion Pharmaceuticals Inc
  • Allergan plc
  • Ambry Genetics
  • Amgen, Inc
  • AstraZeneca plc
  • Bayer AG
  • Berry Genomics Co Ltd.
  • Biogen
  • BioMarin Pharmaceutical Inc
  • Bristol Myers Squibb
  • Celgene
  • CRISPR Therapeutics AG
  • CSL Behring
  • Dr. Reddy’s Laboratories Limited
  • Eli Lilly & Co
  • Enzo Biochem, Inc
  • Evotec AG
  • Exelixis
  • Genmab
  • Gilead Sciences
  • GlaxoSmithKline
  • Grifols International S.A.
  • Guardant Health
  • Illumina
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co, Inc.
  • Mylan
  • Myriad Genetics
  • Novartis International AG
  • Novo Nordisk A/S
  • Organogenesis
  • Oxford Nanopore Technologies
  • Perkin Elmer, Inc
  • Pfizer
  • Precision BioSciences Inc
  • QIAGEN N.V.
  • Regeneron Pharmaceuticals
  • Roche Ltd.
  • Sanofi
  • Seattle Genetics, Inc
  • Shire
  • Takeda
  • Teva Pharmaceutical Industries, Ltd.
  • Thermo Fisher Scientific, Inc
  • UCB S.A.
  • United Therapeutics Corporation
  • Waters Corporation
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll